by John R. Fischer
, Senior Reporter | September 12, 2017
Hologic Inc.’s Brevera breast biopsy system is now available to U.S. consumers, following FDA approval.
The system is the first breast biopsy solution that allows radiologists to image and examine the results of tissue samples in the same room as patients, thereby streamlining the procedures of tissue acquisition, real-time imaging, sample verification and advanced post-biopsy into one system for enhanced workflow.
“The Brevera system's imaging technology verifies tissue samples in real time, delivering information directly to radiologists at the point of care and cutting the current stereotactic breast biopsy procedure from eight steps down to only three,” John Rau, the senior director of global marketing at Hologic, told HCB News. “The Brevera system's real time imaging technology eliminates the need for radiologists to tie up additional facility resources, like another room and imaging system, which, for example, could be used for screening instead.”
For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
Radiologists currently must leave patients under compression and move to a different room to image and verify tissue samples, causing procedures to stretch out for long periods of time and creating anxiety in nervous patients. This can also interrupt screening schedules in a facility.
The Brevera system allows doctors to remain in the same room as patients while imaging tissue samples and retrieving results in a few seconds, decreasing time of procedures by up to 25 percent and reducing discomfort as well as time for each patient by ten minutes. It is designed for use in 2-D and 3-D biopsies and is equipped with a disposable needle to reduce waste management costs.
The solution uses CorLumina imaging technology to manage the process for collecting and separating tissue samples, and to send samples to pathology labs, eliminating the need for manual delivery and the risk of potential contamination. It also offers PACS integration for advanced image sharing capabilities and the transfer of patient files.
Rau is certain that the Brevera system will become a standard tool for conducting breast biopsies.
“To be successful, facilities need to save time, reduce costs and have high patient satisfaction, and the Brevera system is designed to deliver all of that,” he said.
The Brevera system can be used with Hologic's Affirm prone biopsy system, Affirm breast biopsy guidance system and MultiCare Platinum system, and most upright and prone systems on the market.
The U.S. is the first country to approve the sale of the solution. It is currently awaiting CE marking in Europe.
Back to HCB News